Barinthus Biotherapeutics (BRNS) Income from Continuing Operations (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Income from Continuing Operations came in at 5534000.0 in Q1 2026, up 71.85% YoY from 3220276.24 in Q1 2025, and up 50.16% on a QoQ basis from 11103000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Income from Continuing Operations data on file, last reported at 5534000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 71.85% year-over-year to 5534000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 52334000.0 (up 19.88% YoY) and the FY2025 annual result came in at 66458000.0, down 8.62% from the prior year.
- Income from Continuing Operations improved to 5534000.0 in Q1 2026, from 11103000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 15689000.0 in Q2 2022 to a low of 23824000.0 in Q2 2023.
- A 5-year average of 11841235.29 and a median of 15520000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 216.71% — and 2023, when it sank 807.96%.
- Tracing BRNS's Income from Continuing Operations over 5 years: stood at 21163000.0 in 2022, then grew by 18.3% to 17290000.0 in 2023, then decreased by 19.09% to 20591000.0 in 2024, then jumped by 46.08% to 11103000.0 in 2025, then surged by 50.16% to 5534000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 5534000.0 (Q1 2026), 11103000.0 (Q4 2025), and 14571000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | -10.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.60 Mn |
| Mar 31, 2026 | -5.53 Mn |
| Dec 31, 2025 | -11.10 Mn |
| Sep 30, 2025 | -14.57 Mn |
| Jun 30, 2025 | -21.13 Mn |
| Mar 31, 2025 | -19.66 Mn |
| Dec 31, 2024 | -20.59 Mn |
| Sep 30, 2024 | -8.13 Mn |
| Jun 30, 2024 | -16.94 Mn |
| Mar 31, 2024 | -15.52 Mn |
| Dec 31, 2023 | -17.29 Mn |
| Sep 30, 2023 | -14.11 Mn |
| Jun 30, 2023 | -23.82 Mn |
| Mar 31, 2023 | -18.22 Mn |
| Dec 31, 2022 | -21.16 Mn |
| Sep 30, 2022 | 8.22 Mn |
| Jun 30, 2022 | 15.69 Mn |
| Mar 31, 2022 | 2.57 Mn |
| Dec 31, 2021 | -16.82 Mn |
| Sep 30, 2021 | -7.04 Mn |